Expert Opinion on Biological Therapy

Papers
(The TQCC of Expert Opinion on Biological Therapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli107
Antibody drug conjugates for glioblastoma: current progress towards clinical use53
Aflibercept biosimilars – so near, yet so far52
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases51
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease45
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?39
The endosomal-lysosomal system in ADC design and cancer therapy39
Biosimilars and access to biologic therapy in immune-mediated diseases37
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males37
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol33
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)31
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?30
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies30
Correction30
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma30
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era28
Long-acting delivery and therapies for neovascular age-related macular degeneration27
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors25
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences24
Signaling new therapeutic opportunities: cytokines in prostate cancer23
Correction21
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway21
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden21
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing21
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)20
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment20
A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers18
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents18
Moving toward personalized approaches in the management of lupus nephritis17
Need for a risk-based control strategy for managing glycosylation profile for biosimilar products17
Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in u17
Unmet needs in cervical cancer – can biological therapies plug the gap?16
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study16
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?16
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies15
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology15
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy15
Strategies for extending the half-life of biotherapeutics: successes and complications15
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities14
Dynamics of biological markets with multiple biosimilar competitors in the United States14
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe14
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors14
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives14
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses14
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma14
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer13
The nail in psoriatic arthritis: new insights into prognosis and treatment13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis13
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy13
Where do we stand with radioimmunotherapy for acute myeloid leukemia?13
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease13
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective13
Management of proctitis in ulcerative colitis and the place of biological therapies13
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?13
Biological agents targeting interleukin-13 for atopic dermatitis12
Recent advances in delivering RNA-based therapeutics to mitochondria12
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children12
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region12
Emerging peptide-based technology for biofilm control12
Current status of developing tissue engineering vascular technologies12
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-1912
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project11
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials11
De-escalation of anti-CD20 monoclonal antibody (Rituximab) protocols in Pemphigus Vulgaris – a systematic review11
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection11
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward11
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?11
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease11
Classification and coding of platelet-rich plasma derived from New Zealand white rabbits for tissue engineering and regenerative medicine applications11
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma10
An evaluation of pozelimab for the treatment of CHAPLE disease10
Belimumab patient profile in Spain: evolution during the last decade and future directions10
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan10
Personalizing immunotherapy for renal cell carcinoma: how far have we come?10
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents10
Non-traditional approaches for control of antibiotic resistance10
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives10
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?10
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis10
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations10
Epcoritamab in B-cell malignancies: current status and prospects9
Prostate cancer immunotherapy9
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside9
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease9
Clinical management and innovation in fracture non-union9
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study9
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)9
Correction9
Sargramostim in acute radiation syndrome9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer9
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma9
Antibody therapeutics for epithelial ovarian cancer9
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks9
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era9
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio9
Prospects of cell chemotactic factors in bone and cartilage tissue engineering9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target9
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study9
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms9
Treating psoriasis in the elderly: biologics and small molecules9
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective9
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials9
X-linked myotubular myopathy: an untreated treatable disease9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries8
Biologics in rectal cancer8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis8
Rilonacept for the treatment of recurrent pericarditis8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells8
Ravulizumab for the treatment of myasthenia gravis8
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer8
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study8
Hemophilia A gene therapy: current and next-generation approaches8
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk8
The future of cancer vaccines against colorectal cancer7
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?7
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa7
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease7
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto7
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz7
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars7
The future of interleukin gene therapy in head and neck cancers7
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa7
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus7
Rotavirus vaccines: progress and new developments7
CAR T cells for solid tumors – developments to watch in 20237
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting7
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?7
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study7
The future of cellular therapy for the treatment of renal cell carcinoma7
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy7
Belantamab mafodotin in multiple myeloma7
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies7
0.099248886108398